Onsdag 12 Mars | 12:25:41 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-25 06:00 Bokslutskommuniké 2025
2025-11-26 06:00 Kvartalsrapport 2025-Q3
2025-08-27 06:00 Kvartalsrapport 2025-Q2
2025-06-19 N/A X-dag ordinarie utdelning ACOU 0.00 SEK
2025-06-18 N/A Årsstämma
2025-05-28 06:00 Kvartalsrapport 2025-Q1
2025-04-09 N/A Extra Bolagsstämma 2025
2025-02-14 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-22 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning ACOU 0.00 SEK
2024-04-30 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-07 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-04-26 - X-dag ordinarie utdelning ACOU 0.00 SEK
2023-04-25 - Årsstämma
2023-02-22 - Bokslutskommuniké 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-18 - Kvartalsrapport 2022-Q1
2022-04-28 - X-dag ordinarie utdelning ACOU 0.00 SEK
2022-04-27 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-12-21 - Extra Bolagsstämma 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-04-28 - Årsstämma
2021-04-15 - X-dag ordinarie utdelning ACOU 0.00 SEK
2021-02-24 - Bokslutskommuniké 2020
2020-11-25 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-06-10 - X-dag ordinarie utdelning ACOU 0.00 SEK
2020-06-09 - Årsstämma
2020-05-27 - Kvartalsrapport 2020-Q1
2020-02-25 - Bokslutskommuniké 2019
2019-11-20 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-18 - X-dag ordinarie utdelning ACOU 0.00 SEK
2019-06-17 - Årsstämma
2019-05-22 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-06-14 - X-dag ordinarie utdelning ACOU 0.00 SEK
2018-06-13 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-03-21 - Extra Bolagsstämma 2018
2018-02-28 - Bokslutskommuniké 2017
2017-11-24 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-06-19 - X-dag ordinarie utdelning ACOU 0.00 SEK
2017-06-16 - Årsstämma
2017-05-15 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-11-25 - Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
AcouSort är verksamt inom medicinteknik. Idag har bolaget en utvecklad plattformsteknologi inriktad mot akustofores, som med hjälp utav ultraljud separerar och analyserar biologiska cellers sammansättningar. Tekniken används huvudsakligen vid analys av cancerfall och sepsis (blodförgiftning). En stor del av forskningen sker i samarbete med övriga aktörer inom Life-Science. Bolaget etablerades under 2010 och har sitt huvudkontor i Lund.
2025-03-03 12:10:00

AcouSort AB (“AcouSort”) and Bio-ReCell Ltd (“Bio-ReCell”) announce that the two companies have signed a Letter of Intent to jointly explore developing a system for automated clean-up and isolation of stem cells and immune cells from adipose tissue. The core technology in the new system will be based on AcouSort’s unique acoustofluidic expertise and Bio-Recell’s efficient digestion and isolation capabilities.

The first step of the collaboration was a very successful initial trial at AcouSort’s facility in Lund where the applicability of AcouSort’s acoustic separation technology was tested on output from Bio-Recell’s Revive system.

AcouSort and Bio-ReCell share a common interest in providing the healthcare market with innovative solutions improving the efficacy of development and production of advanced therapies leading to better patient outcome upon treatment. Whereas Bio-ReCell’s technology is capable of efficient isolation of a wide range of cell types from complex mixtures, such as adipose tissue, AcouSort’s technology enables purification and up-concentration of cells from these bio-samples or tissue cultures. The two companies will now move forward to optimize and adopt AcouSort’s separation technology to accommodate Bio-ReCell’s specific requirements.

“Collaboration is at the very heart of AcouSort, and it is with great joy we enter into this promising and very exciting partnership. AcouSort and Bio-ReCell share the same vision and deep desire to develop and provide innovative and effective solutions that further improve patient outcomes,” says Torsten Freltoft, AcouSort CEO.

"Advancing technological excellence requires the synergy of compatible and forward-thinking partners. When these partners are industry leaders, success becomes even more attainable. Our collaboration with AcouSort exemplifies this principle, as we combine our expertise to drive innovation in cell therapy. Together, we are committed to revolutionizing the field by leveraging our joint competencies to push the boundaries of what’s possible.” says Dr. Luka Fajs, Bio-ReCell’s CEO.

About Bio-ReCell
Bio-ReCell is at the cutting edge of biotechnology, leading the advancement towards improved isolation of specific cell types from complex mixtures. Our team comprises experts who are pioneers in their field. United by our shared passion for Cell Biology, we are dedicated to bringing the benefits of our technological innovations to the world.